### ü´Å Critical Care Medicine: Lithium Toxicity

#### ‚úÖ True Statements
1. **Lithium** is an effective treatment for **bipolar disorder** but has a **narrow therapeutic window**, and toxicity is common.
2. Risk factors for **lithium toxicity** include **increased age**, **hypovolemia**, and **kidney disease**.
3. Early symptoms of **lithium toxicity** are **gastrointestinal**, including **nausea**, **vomiting**, and **diarrhea**, which may be mistaken for gastrointestinal infection.
4. Later and more severe symptoms of **lithium toxicity** include **agitation**, **confusion**, **ataxia**, **tremor**, and **myoclonic jerks**.
5. **Arginine vasopressin resistance** (formerly called **nephrogenic diabetes insipidus**) is a common complication of **lithium toxicity** and results in **hypernatremia** and **volume depletion**.
6. The diagnosis of **lithium toxicity** is confirmed by an **elevated serum lithium level**.
7. Management of **lithium toxicity** includes **volume resuscitation** and **careful serum sodium management**.
8. **Hemodialysis** is indicated if the **serum lithium level is >4 mEq/L (4 mmol/L)** or if severe symptoms such as **seizure** or **coma** are present.

#### üí¨ Extra
3. Gastrointestinal features may precede neurologic symptoms, leading to diagnostic delay.
5. Arginine vasopressin resistance from lithium can mimic diabetes insipidus and cause dehydration.
8. Indications for dialysis are based on both serum level and clinical severity.

#### üè∑Ô∏è Tags
#CriticalCare #Toxicology #Lithium #BipolarDisorder #Hemodialysis #Electrolytes

#### üìö Reference
Chan BS, Cheng S, Isoardi KZ, et al. Effect of age on the severity of chronic lithium poisoning. *Clin Toxicol (Phila)*. 2020;58:1023-7. PMID: 32068433 doi:10.1080/15563650.2020.1726376

#### üÜî Question ID
CCMCQ24006

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Critical Care Medicine ‚Äî Specific Critical Care Topics, Toxicology, Overdose of Therapeutic Drugs

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Overdose of Therapeutic Drugs
1. Patients may overdose on prescribed medications **inadvertently or intentionally**.
2. Ingestion of **multiple medications** is common in drug overdoses, as is **concomitant ethanol ingestion**.
3. Important factors in determining the nature of a drug overdose include **suicidal ideation or intent**, **medications prescribed to the patient and family members**, **which prescriptions were filled**, **events reported by the patient or bystanders**, and **clinical signs and symptoms**.
4. If patients are **alert and cooperative enough to protect their airway**, **activated charcoal** may be beneficial when administered **within 1 to 2 hours of ingestion**.

#### üí¨ Extra
3. A thorough history of prescriptions and collateral information is critical for overdose evaluation.
4. Airway protection is the limiting factor for activated charcoal use.

#### üè∑Ô∏è Tags
#CriticalCare #Toxicology #DrugOverdose #ActivatedCharcoal #EmergencyMedicine

---

#### üóæ Supplemental Tables

<!-- Presentation and Treatment of Therapeutic Drug Toxicities -->
<table>
  <caption><strong>Presentation and Treatment of Therapeutic Drug Toxicities</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Key Clinical Findings</th>
      <th>Treatment</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <!-- Nonopioid analgesics -->
    <tr>
      <td colspan="4"><strong>Nonopioid analgesics</strong></td>
    </tr>
    <tr>
      <td>Acetaminophen</td>
      <td>‚Üë Liver chemistry studies, ‚Üë creatinine, ‚Üë INR, encephalopathy, cerebral edema, vomiting</td>
      <td><em>N</em>-acetylcysteine</td>
      <td>Transfer to liver transplant center if severe</td>
    </tr>
    <tr>
      <td>Salicylates</td>
      <td>Mixed respiratory alkalosis/anion gap metabolic acidosis, tinnitus, agitation, confusion, hyperthermia</td>
      <td>Forced diuresis, bicarbonate infusion, glucose</td>
      <td>Target urine pH 7.5‚Äì8.0 with serum pH &lt;7.55; hemodialysis if acute kidney injury or severe toxicity</td>
    </tr>
    <!-- Cardiovascular -->
    <tr>
      <td colspan="4"><strong>Cardiovascular</strong></td>
    </tr>
    <tr>
      <td>Œ≤-Blocker, calcium channel blocker</td>
      <td>Bradycardia, hypotension, heart block; altered mental status with Œ≤-blocker</td>
      <td>Atropine, 1 mg IV (up to three doses), glucagon, calcium chloride, vasopressors, cardiac pacemaker (if indicated), high-dose insulin and glucose, IV lipid emulsion</td>
      <td>Treatments may be added sequentially or initiated simultaneously on the basis of severity and treatment response</td>
    </tr>
    <tr>
      <td>Digoxin</td>
      <td>Bradycardia, arrhythmia, nausea, emesis, abdominal pain, confusion, weakness</td>
      <td>Digoxin-specific antibody (if hyperkalemic or life-threatening arrhythmia)</td>
      <td>Use of antibody lowers potassium; hemodialysis not effective</td>
    </tr>
    <!-- Anticholinergics -->
    <tr>
      <td colspan="4"><strong>Anticholinergics</strong></td>
    </tr>
    <tr>
      <td>Tricyclic antidepressants</td>
      <td>Hypotension, sedation, seizure, anticholinergic signs, prolonged QRS, arrhythmia</td>
      <td>Bicarbonate infusion titrated to QRS duration; benzodiazepines for seizure</td>
      <td>Physostigmine contraindicated</td>
    </tr>
    <tr>
      <td>Antihistamines</td>
      <td>Anticholinergic signs, including agitation and seizures</td>
      <td>Benzodiazepines; physostigmine if isolated anticholinergic overdose</td>
      <td>Physostigmine use requires continuous cardiac monitor and bedside atropine</td>
    </tr>
    <!-- Hypoglycemic -->
    <tr>
      <td colspan="4"><strong>Hypoglycemic</strong></td>
    </tr>
    <tr>
      <td>Sulfonylurea</td>
      <td>‚Üì Glucose, confusion, seizure, anxiety, diaphoresis, tremor</td>
      <td>IV glucose + octreotide; intramuscular glucagon = temporizing measure until IV access</td>
      <td>Monitor for ‚Üì glucose for 48 hours if large ingestion</td>
    </tr>
    <tr>
      <td>Metformin</td>
      <td>‚Üë Lactate, abdominal pain</td>
      <td>Hemodialysis for severe acidemia or acute kidney injury</td>
      <td>Glucose usually normal if isolated metformin ingestion</td>
    </tr>
    <!-- Others -->
    <tr>
      <td colspan="4"><strong>Others</strong></td>
    </tr>
    <tr>
      <td>Lithium</td>
      <td>GI distress, agitation, confusion, ataxia, tremor, myoclonic jerks, arginine vasopressin resistance (and resulting hypernatremia). GI symptoms early, neurologic findings later (irreversible neurologic impairment possible)</td>
      <td>General management: volume resuscitation, careful serum sodium level management; serial lithium levels. Hemodialysis if lithium level &gt;4 mEq/L (4 mmol/L) or severe symptoms</td>
      <td>Serum level can guide need for hemodialysis, confirm diagnosis. Age, hypovolemia, and kidney failure are predisposing factors</td>
    </tr>
    <tr>
      <td>SSRI/SNRI</td>
      <td>Agitation, myoclonus, ‚Üë reflexes, rigidity, fever, tachycardia</td>
      <td>Benzodiazepines, cyproheptadine if severe</td>
      <td>‚Üë Cardiac toxicity with venlafaxine</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="4">
        <em>GI = gastrointestinal; IV = intravenous; SNRI = serotonin norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor.</em>
      </td>
    </tr>
  </tfoot>
  <p><em>GI = gastrointestinal; IV = intravenous; SNRI = serotonin norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor.</em></p>
</table>

#### ‚úÖ True Statements (from Table: Presentation and Treatment of Therapeutic Drug Toxicities)
1. **Acetaminophen toxicity** presents with **elevated liver chemistry studies**, **elevated creatinine**, **elevated international normalized ratio (INR)**, **encephalopathy**, **cerebral edema**, and **vomiting**, and is treated with **N‚Äëacetylcysteine**.
2. Severe **acetaminophen toxicity** warrants **transfer to a liver transplant center**.
3. **Salicylate toxicity** causes **mixed respiratory alkalosis with anion gap metabolic acidosis** and may produce **tinnitus**, **agitation**, **confusion**, and **hyperthermia**.
4. Treatment of **salicylate toxicity** includes **forced diuresis**, **bicarbonate infusion**, and **glucose**.
5. For **salicylate toxicity**, **urine pH should be targeted to 7.5‚Äì8.0** while **serum pH remains &lt;7.55**; **hemodialysis** is indicated with **acute kidney injury** or **severe toxicity**.
6. **Œ≤‚ÄëBlocker and calcium channel blocker toxicity** presents with **bradycardia**, **hypotension**, and **heart block**; **altered mental status** is specifically noted with **Œ≤‚Äëblocker toxicity**.
7. Treatment options for **Œ≤‚Äëblocker or calcium channel blocker overdose** include **atropine (1 mg IV up to three doses)**, **glucagon**, **calcium chloride**, **vasopressors**, **cardiac pacing (if indicated)**, **high‚Äëdose insulin with glucose**, and **intravenous lipid emulsion**.
8. In **Œ≤‚Äëblocker or calcium channel blocker overdose**, therapies may be **added sequentially** or **initiated simultaneously** based on **severity** and **treatment response**.
9. **Digoxin toxicity** presents with **bradycardia**, **arrhythmia**, **nausea**, **emesis**, **abdominal pain**, **confusion**, and **weakness**.
10. **Digoxin‚Äëspecific antibody** is indicated for **hyperkalemia** or **life‚Äëthreatening arrhythmia** due to **digoxin toxicity**.
11. **Digoxin‚Äëspecific antibody** administration **lowers serum potassium**, and **hemodialysis is not effective** for digoxin removal.
12. **Tricyclic antidepressant overdose** may cause **hypotension**, **sedation**, **seizure**, **anticholinergic signs**, **prolonged QRS**, and **arrhythmia**.
13. Treatment of **tricyclic antidepressant overdose** includes **sodium bicarbonate infusion titrated to QRS duration** and **benzodiazepines for seizures**.
14. **Physostigmine is contraindicated** in **tricyclic antidepressant overdose**.
15. **Antihistamine overdose** can produce **anticholinergic signs** including **agitation** and **seizures**.
16. Treatment of **antihistamine overdose** includes **benzodiazepines**, with **physostigmine** considered **only in isolated anticholinergic overdose**.
17. **Physostigmine use** in anticholinergic toxicity **requires continuous cardiac monitoring** and **bedside atropine**.
18. **Sulfonylurea overdose** is associated with **hypoglycemia**, **confusion**, **seizure**, **anxiety**, **diaphoresis**, and **tremor**.
19. Treatment of **sulfonylurea overdose** includes **intravenous glucose** and **octreotide**; **intramuscular glucagon** is a **temporizing measure** until **intravenous access** is available.
20. After a **large sulfonylurea ingestion**, **blood glucose should be monitored for 48 hours**.
21. **Metformin overdose** may present with **elevated lactate** and **abdominal pain**.
22. **Hemodialysis** is used for **severe acidemia** or **acute kidney injury** due to **metformin overdose**; **glucose is usually normal** when **metformin** is ingested **in isolation**.
23. In **lithium toxicity**, **serial lithium levels** are part of management, and **neurologic findings may occur later** with a possibility of **irreversible neurologic impairment**.
24. **SSRI/SNRI toxicity** may cause **agitation**, **myoclonus**, **hyperreflexia**, **rigidity**, **fever**, and **tachycardia** and is treated with **benzodiazepines**; **cyproheptadine** is used **if severe**.
25. **Venlafaxine** is associated with **increased cardiac toxicity** among **serotonergic antidepressants**.

#### üí¨ Extra (from Table)
5. **Alkalinization targets** are explicitly specified in the table to guide **urinary trapping** of salicylates while avoiding systemic alkalemia.
7. **Atropine dosing** is limited to **1 mg IV per dose** for **up to three doses** as listed.
11. The **potassium‚Äëlowering effect** after digoxin Fab administration is a table note to anticipate electrolyte changes.
19. **Glucagon** provides a **temporary increase in heart rate and blood pressure** while IV access is obtained for dextrose and octreotide therapy in sulfonylurea overdose‚Äîcaptured here as a process clarification from the table wording.
22. The table specifies that **normal glucose** is expected in **isolated metformin ingestion**, avoiding unnecessary dextrose therapy.
